Based on the available information, it is not possible to definitively conclude that aspirin increases bleeding risk more than new antiplatelets.

The article from the American College of Cardiology (ACC) [3] provides an expert consensus decision pathway on the role of anticoagulation and antiplatelet therapy, but it does not provide a direct comparison of bleeding risks between aspirin and new antiplatelets.

The National Center for Biotechnology Information (NCBI) article [2] discusses the use of antiplatelet therapy for the prevention of recurrent stroke, but it does not specifically compare the bleeding risks of aspirin and new antiplatelets.

The Drug Patent Watch page on aspirin [1] provides information on the drug's patents and expirations, but it does not contain any data on bleeding risks.

Therefore, while it is known that both aspirin and new antiplatelets can increase the risk of bleeding [2][3], a direct comparison of the bleeding risks between aspirin and new antiplatelets cannot be made solely based on the provided information.

Sources:

1. <https://www.drugpatentwatch.com/p/tradename/ASPIRIN>
2. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901154/>
3. <https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2020/12/17/21/04/2020-ACC-Expert-Consensus-Anticoagulant-Antiplatelet>